Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.

about

Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.

Item

http://www.wikidata.org/entity/Q48156924

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Prognostic impact of immunopar ...... with light-chain amyloidosis.

@en

Prognostic impact of immunopar ...... with light-chain amyloidosis.

@nl

type

Item

label

Prognostic impact of immunopar ...... with light-chain amyloidosis.

@en

Prognostic impact of immunopar ...... with light-chain amyloidosis.

@nl

prefLabel

Prognostic impact of immunopar ...... with light-chain amyloidosis.

@en

Prognostic impact of immunopar ...... with light-chain amyloidosis.

@nl

P1476

Prognostic impact of immunopar ...... s with light-chain amyloidosis

@en

P2093

Ignacio Isola

http://www.w3.org/2001/XMLSchema#string

Natalia Tovar

http://www.w3.org/2001/XMLSchema#string

Tania Díaz

http://www.w3.org/2001/XMLSchema#string

P2860

Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy

Systemic amyloidosis.

Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma

Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma.

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Review of 1027 patients with newly diagnosed multiple myeloma.

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma.

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.

Survival analysis in hematologic malignancies: recommendations for clinicians

P304

245-252

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13506129.2017.1390451

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Juan I Arostegui

Ester Lozano

Carlos Fernández de Larrea

Luis Gerardo Rodríguez-Lobato

P577

2017-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29052436

http://www.w3.org/2001/XMLSchema#string